Proactive Investors - Run By Investors For Investors

Tilray shorts fell by about 45,000 in the past week, says S3 Partners

But the drop in the number of shares shorted is not a squeeze in the market
Cannabis workers
The Canadian cannabis company's shares have become a battleground stock

The number of shares that are being shorted in Tilray Inc (NASDAQ:TLRY) has gone down by about 45,000 over the last week, a report by analytics company S3 Partners said on Wednesday.

Ihor Dusaniwsky said in a tweet the short interest in the Canadian cannabis company at this time is worth $385 million and the number of shares shorted stands at 3.57 million, accounting for 34.63% of the bloat.

Dusaniwsky said the fall in the number of shares shorted is “in no way a short squeeze as the stock was down 7% and shorts were up $128 million in mark-to-market profits.”

READ: Waiting to inhale? Cannabis stocks like Tilray are only going to go higher

Borrowing costs are now ranging from 50% to 70% fee, compared with the 500%-700% fee levels at the height of the rally in the stock last week when the share price charged to an all-time peak of $300.

Tilray is a Canadian cannabis company where market bulls and bears are battling it out, with the bulls pointing to the upcoming legalization of cannabis in Canada and short sellers claiming the stock is overvalued.

Shares were trading 4.34% higher at $112.56 late on Wednesday.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full TLRY profile View Profile

Tilray Inc Timeline

Related Articles

Woman holding cannabis leaf
October 16 2018
Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 30 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use